TY - JOUR
T1 - Hyaluronic acid and hyaluronic acid
T2 - Sucrose nanogels for hydrophobic cancer drug delivery
AU - Sagbas Suner, Selin
AU - Ari, Betul
AU - Onder, Ferah Comert
AU - Ozpolat, Bulent
AU - Ay, Mehmet
AU - Sahiner, Nurettin
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Porous and biodegradable hyaluronic acid (HA) nanogel and their copolymeric forms with sucrose (Suc), HA:Sucrose (HA:Suc) nanogels, were synthesized by employing glycerol diglycidyl ether (GDE) as crosslinker with a single step reaction in surfactant-free medium. The size of the nanogels was determined as 150 ± 50 nm in dried state from SEM images and found to increase to about 540 ± 47 nm in DI water measured with DLS measurements. The surface areas of HA and HA:Suc nanogels were measured as 18.07 ± 2.4 and 32.30 ± 6.1 m2/g with porosities of 3.58 ± 1.8, and 9.44 ± 3.1 nm via BET analysis, respectively. The zeta potentials for HA and HA:Suc nanogels were measured as −33 ± 1.4 and − 30 ± 1.2 mV, respectively. The thermal degradation of both types of nanogels revealed similar trends, while hydrolytic degradation of the nanogels was about 22.7 ± 0.2 wt% in 15 days. Both HA and HA:Suc nanogels were stable in blood up to 250 μg/mL concentration with approximately 0.5 ± 0.1% hemolysis ratio and 76 ± 12% blood clotting indices, respectively. Finally, these nanogels were used as a sustained slow-release or long-term delivery system over 2 days for a hydrophobic cancer drug, 3‑((E)‑3‑(4‑hydroxyphenyl)acryloyl)‑2H‑chromen‑2‑on (A#) established by our group. The nanogels successfully delivered the model drug A at 10.43 ± 2.12 mg/g for 2 days.
AB - Porous and biodegradable hyaluronic acid (HA) nanogel and their copolymeric forms with sucrose (Suc), HA:Sucrose (HA:Suc) nanogels, were synthesized by employing glycerol diglycidyl ether (GDE) as crosslinker with a single step reaction in surfactant-free medium. The size of the nanogels was determined as 150 ± 50 nm in dried state from SEM images and found to increase to about 540 ± 47 nm in DI water measured with DLS measurements. The surface areas of HA and HA:Suc nanogels were measured as 18.07 ± 2.4 and 32.30 ± 6.1 m2/g with porosities of 3.58 ± 1.8, and 9.44 ± 3.1 nm via BET analysis, respectively. The zeta potentials for HA and HA:Suc nanogels were measured as −33 ± 1.4 and − 30 ± 1.2 mV, respectively. The thermal degradation of both types of nanogels revealed similar trends, while hydrolytic degradation of the nanogels was about 22.7 ± 0.2 wt% in 15 days. Both HA and HA:Suc nanogels were stable in blood up to 250 μg/mL concentration with approximately 0.5 ± 0.1% hemolysis ratio and 76 ± 12% blood clotting indices, respectively. Finally, these nanogels were used as a sustained slow-release or long-term delivery system over 2 days for a hydrophobic cancer drug, 3‑((E)‑3‑(4‑hydroxyphenyl)acryloyl)‑2H‑chromen‑2‑on (A#) established by our group. The nanogels successfully delivered the model drug A at 10.43 ± 2.12 mg/g for 2 days.
KW - Cancer drug delivery
KW - Degradable microgel/nanogels
KW - Hyaluronic acid/sucrose
KW - Sustained delivery therapy
UR - http://www.scopus.com/inward/record.url?scp=85059752378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059752378&partnerID=8YFLogxK
U2 - 10.1016/j.ijbiomac.2019.01.021
DO - 10.1016/j.ijbiomac.2019.01.021
M3 - Article
C2 - 30625351
AN - SCOPUS:85059752378
SN - 0141-8130
VL - 126
SP - 1150
EP - 1157
JO - International Journal of Biological Macromolecules
JF - International Journal of Biological Macromolecules
ER -